Faron Pharmaceuticals Oy (FARN) Price & Analysis

Compare

61 Followers

FARN Stock Chart & Stats

48.60p

-2.73p(-1.37%)

At close: Jan 09 4:00 PM EST

48.60p

-2.73p(-1.37%)

Day’s Range― - ―

52-Week Range44.00p - 270.00p

Previous CloseN/A

Volume750.00

Average Volume (3M)46.62K

Market Cap

£52.77M

Enterprise Value270.38M

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.89

Next Earnings

Mar 04, 2026

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding115,783,960

10 Day Avg. Volume70,409

30 Day Avg. Volume46,616

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£1,000.00

Price Target Upside1957.61% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Capital Efficiency And PartnerabilityA design that lowers patient enrollment needs and advances studies without awaiting a commercial partner improves capital efficiency and increases attractiveness to potential pharmaceutical collaborators or acquirers.

Clinical DifferentiationConsistent, deep responses across high-risk subgroups, including TP53-mutated patients, and signals of disease-modifying activity position the therapy as a differentiated, potentially curative option in high-risk myelodysplastic syndromes.

Regulatory StrategyShifting the primary approval endpoint to complete response with duration and using a staged program with an initial smaller study followed by a confirmatory trial may reduce regulatory uncertainty and enable structured check-ins before committing major resources.

Bears Say

Clinical Development RiskReliance on future trial results to confirm early promising outcomes creates substantial clinical development risk that could delay approval or require additional studies.

Commercialization RiskCommercial success is uncertain due to potential challenges in scaling manufacturing, obtaining payer coverage, and integrating the therapy into existing treatment pathways.

Competitive LandscapeAdvances by competitors in immunotherapies or alternative treatments could reduce the therapy's market opportunity if rivals report superior efficacy or secure earlier regulatory approvals.

Faron Pharmaceuticals Oy News

De-Risked Development Path and Strong BEXMAB Efficacy Drive Reiterated Buy on Faron and £10 Target

Faron Pharmaceuticals Oy, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio...

2d ago

Faron plans €40m rights issue to fund bexmarilimab through key cancer trial milestones

Faron Pharmaceuticals Oy ( ($GB:FARN) ) just unveiled an announcement. Faron Pharmaceuticals plans to launch a rights offering...

15d ago

Faron Registers 909,517 New Shares After Exercise of Special Rights

Faron Pharmaceuticals Oy ( ($GB:FARN) ) just unveiled an update. Faron Pharmaceuticals has registered 909,517 new shares in...

21d ago

Faron Uses Share Settlement to Amortise Convertible Bonds, Adding 909,517 New Shares

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has issued an update. Faron Pharmaceuticals has approved the exercise of 909,517...

22d ago

Faron CFO Sells Entire Personal Stake in Biopharma Group

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has provided an announcement. Faron Pharmaceuticals has disclosed that its Chief Financial...

1M ago

Faron Uses Treasury Shares to Settle Advanced Bond Amortisation and Adjusts Maturity Profile

Faron Pharmaceuticals Oy ( ($GB:FARN) ) just unveiled an update. Faron Pharmaceuticals has approved the exercise of 453,979...

2M ago

Faron Pharmaceuticals Revises Shareholders’ Nomination Board Composition

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has shared an update. Faron Pharmaceuticals Ltd has announced the re-election of...

2M ago

Promising Potential of Faron Pharmaceuticals’ Bexmarilimab in Treating High-Risk Myelodysplastic Syndromes and Solid Tumors Justifies Buy Rating

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Faron Pharmaceuticals Oy and keeping the price...

2M ago

Faron Pharmaceuticals Strengthens Financial Position with EUR 10 Million Bond Issuance

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has provided an update. Faron Pharmaceuticals has issued a second tranche of...

3M ago

Promising Clinical Trial Results and Strategic Advancements Justify Buy Rating for Faron Pharmaceuticals

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Faron Pharmaceuticals Oy today and set a price...

3M ago

FARN FAQ

What was Faron Pharmaceuticals Oy’s price range in the past 12 months?

Faron Pharmaceuticals Oy lowest share price was 44.00p and its highest was 270.00p in the past 12 months.

What is Faron Pharmaceuticals Oy’s market cap?

Faron Pharmaceuticals Oy’s market cap is £52.77M.

When is Faron Pharmaceuticals Oy’s upcoming earnings report date?

Faron Pharmaceuticals Oy’s upcoming earnings report date is Mar 04, 2026 which is in 7 days.

How were Faron Pharmaceuticals Oy’s earnings last quarter?

Faron Pharmaceuticals Oy released its earnings results on Aug 27, 2025. The company reported -0.133p earnings per share for the quarter, beating the consensus estimate of -0.865p by 0.732p.

Is Faron Pharmaceuticals Oy overvalued?

According to Wall Street analysts Faron Pharmaceuticals Oy’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Faron Pharmaceuticals Oy pay dividends?

Faron Pharmaceuticals Oy does not currently pay dividends.

What is Faron Pharmaceuticals Oy’s EPS estimate?

Faron Pharmaceuticals Oy’s EPS estimate is -0.09.

How many shares outstanding does Faron Pharmaceuticals Oy have?

Faron Pharmaceuticals Oy has 115,783,960 shares outstanding.

What happened to Faron Pharmaceuticals Oy’s price movement after its last earnings report?

Faron Pharmaceuticals Oy reported an EPS of -0.133p in its last earnings report, beating expectations of -0.865p. Following the earnings report the stock price went down -4.494%.

Which hedge fund is a major shareholder of Faron Pharmaceuticals Oy?

Currently, no hedge funds are holding shares in GB:FARN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

Faron Pharmaceuticals Oy (FARN) Earnings & Revenues

Historic Earnings Reports

FARN Stock 12 Month Forecast

Average Price Target

1,000.00p

▲(1957.61% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"169":"169p","377":"377p","585":"585p","793":"793p","1001":"1,001p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">1.00K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">1.00K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">1.00K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[169,377,585,793,1001],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,190,252.30769230769232,314.61538461538464,376.9230769230769,439.2307692307692,501.53846153846155,563.8461538461538,626.1538461538462,688.4615384615385,750.7692307692307,813.0769230769231,875.3846153846154,937.6923076923076,{"y":1000,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,190,252.30769230769232,314.61538461538464,376.9230769230769,439.2307692307692,501.53846153846155,563.8461538461538,626.1538461538462,688.4615384615385,750.7692307692307,813.0769230769231,875.3846153846154,937.6923076923076,{"y":1000,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,190,252.30769230769232,314.61538461538464,376.9230769230769,439.2307692307692,501.53846153846155,563.8461538461538,626.1538461538462,688.4615384615385,750.7692307692307,813.0769230769231,875.3846153846154,937.6923076923076,{"y":1000,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":180,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.5,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":170,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":209,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":192.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":252.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":192.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":180,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >